3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
36
Triple Negative Breast Neoplasms
32
Carcinoma, Non-Small-Cell Lung
11
Carcinoma, Transitional Cell
10
Urinary Bladder Neoplasms
9
Neoplasm Metastasis
7
Lung Neoplasms
5
Endometrial Neoplasms
4
Small Cell Lung Carcinoma
3
Ovarian Neoplasms
3
Glioblastoma
3
Brain Neoplasms
3
Uterine Cervical Neoplasms
2
Salivary Gland Neoplasms
2
Pancreatic Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Urothelial Bladder Carcinoma
1
Triple Negative Locally Advanced Non-resectable Breast Cancer
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Recurrence
1
Prostatic Neoplasms, Castration-Resistant
1
Interventions
sacituzumab govitecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Triple Negative Locally Advanced Non-resectable Breast Cancer
×
sacituzumab govitecan
×
Clear all
NCT06827613
2025-09-24
START-002
Marengo Therapeutics, Inc.
Phase 1/2
Recruiting
50 enrolled